M acrophage lipid metabolism and foam cell biology represent key avenues of research in atherosclerosis. Genetic studies of human macrophage biology have been hampered by the lack of a scalable and flexible cell model. Human induced pluripotent stem cells (iPSC)-derived macrophages (IPSDM) can be rapidly generated and genetically edited by CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) and, therefore, represent a powerful platform to study human macrophage biology.
LAL corrects pathogenic phenotypes in Lipa knockout mice, suggesting the central role of macrophages in LAL deficiency pathology. 6 Patients with CESD and atherosclerosis mouse models with Lipa deficiency have accelerated atherosclerosis, but the relative contribution of hyperlipidemia is unknown. Indeed, the role of human LIPA in macrophage lipid metabolism has barely been studied in human macrophages. In this study, we used CRISPR/Cas9 to knock out LIPA in iPSC and then differentiated to IPSDM using our published protocol 1 to explore how loss of function of LIPA in human macrophage affects CE handling, efflux, and gene expression. We demonstrate that application of IPSDM coupled with CRISPR/Cas9 provides a valuable tool for understanding human macrophage-specific LIPA functions.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

LIPA Is Abundantly Expressed in Human Monocyte-Derived Macrophage and IPSDM
We first characterized LIPA expression across different cell lines and primary cells by quantitative reverse transcriptase polymerase chain reaction. LIPA was highly expressed in human peripheral blood mononuclear cell-derived macrophages (HMDM) but was expressed at lower levels in HepG2 (hepatocellular carcinoma cells), peripheral blood mononuclear cells, skin fibroblast, endothelial cells and vascular smooth muscle cells, and iPSC ( Figure I in the online-only Data Supplement). This macrophage-enriched expression pattern suggests a central role of macrophages in systemic LIPA physiology and pathophysiology. 7 LIPA expression was similar between HMDM and IPSDM ( Figure ID in the online-only Data Supplement), as previously thoroughly characterized, 1 supporting IPSDM as a robust model to study macrophage LIPA function.
Knockout of LIPA in iPSC by CRISPR/ Cas9 and Differentiation to IPSDM
A guide RNA targeting exon 7 of the LIPA gene was designed to approximate the exon 8 splice-junction mutation (rs116928232, NM_000235.3:c.894G>A), the most common mutation in CESD leading to the deletion of exon 8 encoding a mutant LAL enzyme with no activity. 8 The parental iPSC line derived from a healthy subject was transiently transfected with plasmids encoding a Cas9-GFP fusion protein and the guide RNA targeting exon 7 of the LIPA gene. Five iPSC clones, either unedited (control) or those with homozygote or compound heterozygote frame shift mutations (LIPA −/− ), were expanded and differentiated ( Figure 1A) . Consistent with the absence of protein expression ( Figure II in the online-only Data Supplement) in LIPA −/− IPSDM, the LIPA −/− IPSDM showed barely detectable LAL enzymatic activity in cell lysate and conditioned media using fluorogenic substrate 4-methylumbelliferyl oleate ( Figure 1B) 
LIPA
−/− Does Not Affect ABCA1-Mediated Efflux Capacity and Lipid Loading-Induced ABCA1 Upregulation in Macrophages
To probe whether impaired cholesterol efflux in [ 3 H]-COAcLDL-loaded LIPA −/− IPSDM may be attributable to the compromised ABCA1 (ATP-binding cassette, subfamily A, member 1)-mediated efflux capacity as has been implicated by studies in LDL-treated skin fibroblasts of CESD patients, 10 we loaded the control and 
LIPA −/− Results in Lysosomal CE Accumulation but Does Not Alter Lysosomal Proteolytic Activity or Macrophage Inflammatory Gene Expression
Cellular CE mass was determined by gas chromatographymass spectrometry and normalized to the amount of protein. In the nonlipid loaded state, LIPA −/− IPSDM showed high levels of CE mass compared with minute amounts of CE in control IPSDM ( Figure 2D) ; this is likely because that LAL deficiency impaired hydrolysis of CE derived from bovine serum lipoprotein (estimated to be ≈160-210 μg/mL in serum) 11 in the culture media. This CE accumulation was, however, not observed in HMDM treated with chloroquine, or Lalistat, an LALspecific pharmacological inhibitor for only 24 hours, suggesting that a sustained deficiency in LAL is required to impact macrophage CE accumulation under physiological lipid loading conditions ( Figure 2E ; Figure III in the online-only Data Supplement). Notably, the increase in lysosomal CE levels in LIPA −/− IPSDM was not associated with changes in the expression of inflammatory genes, such as IL1B, IL6, and CCL5 as determined by quantitative reverse transcriptase polymerase chain reaction and confirmed by RNA sequencing ( Figure IV in the online-only Data Supplement).
In AcLDL-loaded macrophages, CE derived from lipoprotein is hydrolyzed in the lysosome by LAL, and the FC is released and esterified by ACAT to form CE for storage. Human LDL also contains FC, accounting for 20% to 30% of total cholesterol content, 12 which can be released from the lysosome directly. By adding ACATi during lipid loading, the cytoplasmic CE storage is depleted. AcLDL loading induced similar increase in CE mass in both control and LIPA −/− IPSDM. In LIPA −/− IPSDM, CE derived from AcLDL is retained in the lysosome because of impaired LAL function, but FC in the internalized AcLDL can still be released from the lysosome and esterified to form cytoplasmic CE. ACATi treatment inhibited this process and induced ≈50% reduction in CE mass that represents the depleted cytoplasmic CE. And the CE mass detected in the ACATi-treated LIPA −/− IPSDM with AcLDL loading represents the lysosomal CE accumulation (the sixth bar in Figure 2D ). In the control IPSDM with normal LAL function, ACATi completely abolished the CE mass in the AcLDL loading cells (the fifth bar in Figure 2D ), 
Discussion
To date, mechanistic insights into the cell biology of human LIPA have been largely derived from skin fibroblasts of CESD patients. 10, 13 Here, we use CRISPR/Cas9 techniques to knockout LIPA in human iPSC and then differentiate to IPSDM to explore LIPA function in human macrophages. Our findings show that (1) LIPA was expressed abundantly in macrophage; (2) deletion of LIPA abolished the enzymatic activity of LAL in IPSDM; (3) LIPA −/− eliminated lysosomal CE hydrolysis in IPSDM; (4) ABCA1-mediated cholesterol efflux capacity and ABCA1 expression were not impaired in LIPA −/− IPSDM; (5) although LIPA −/− caused marked increase in lysosomal CE accumulation, apolipoprotein B degradation was not affected and the expression of inflammatory genes was not increased. These IPSDM phenotypes were observed across multiple LIPA −/− IPSDM lines and were consistent with findings using chloroquine and Lalistat-treated HMDM. Thus, application of IPSDM coupled with CRISPR/Cas9 provides a powerful platform to understand human macrophage-specific LIPA functions and, more broadly, human macrophage biology.
Studies conducted in skin fibroblasts of CESD patients showed that LIPA deficiency impaired CE hydrolysis, which affected the rate of release of cholesterol from late endosomes/ lysosomes, a critical regulator of ABCA1 expression and activity. 10 In our study, however, we did not observe impaired ABCA1 upregulation by AcLDL loading or reduced ABCA1-mediated
Although this suggests potential cell-specific differences in LIPA metabolic phenotypes between macrophages and fibroblasts, further studies using different conditions are required to reveal the full spectrum of LAL modulation of macrophage lipid, metabolic and inflammatory phenotypes, that is, other modified LDLs, with less efficient lysosomal processing than AcLDL, 14 and may reveal distinct phenotypic manifestations. Moreover, LIPA −/− IPSDM had lysosomal CE accumulation even without AcLDL loading, but this accumulation did not result in increased expression of several inflammatory genes. Whether additional challenges, that is, lipopolysaccharide or other TLR (Toll-like receptor) agonists, may exaggerate the inflammatory response remains to be determined. As LAL-mediated lipolysis was essential for fatty acid oxidation and M2 activation in murine macrophage, 7 and LAL expression and activity was lower in M1-activated HMDM by lipopolysaccharide and interferon-gamma but higher in M2-HMDM by interleukin-4 ( Figure VI in the online-only Data Supplement), the role of human LIPA, and its genetic variation, in human macrophage M2 activation can also be studied using LIPA −/− IPSDM. Although LIPA loss of function in CESD was associated with accelerated atherosclerosis, 8 recent genome-wide association studies have identified LIPA alleles that increase risk for coronary artery disease [15] [16] [17] are also associated with higher LIPA mRNA in monocytes 15 and macrophages. 18 These paradoxical data raise important questions on the directionality of coronary artery disease causal variant(s) at the LIPA locus. A recent study by Morriss et al 19 suggested that rs1051338, a coding variant in high linkage disequilibrium with the genome-wide association studies lead singlenucleotide polymorphisms, may serve as the potential causal variant at the LIPA locus for coronary artery disease by showing that lysosomal LAL activity of HMDM in the risk allele carriers was lower than that in the nonrisk allele carriers. Yet, these data do not address the paradox of the risk alleles being associated with increased LIPA expression. Thus, the functional impact and mechanisms of the causal variants on macrophage phenotypes remain to be fully defined. Future studies using IPSDM differentiated from isogenic iPSC lines with CRISPR/Cas9-mediated knockin of LIPA risk alleles will reveal the causal effects of any individual or combination of single-nucleotide polymorphisms variants. Our study using LIPA −/− IPSDM reveals macrophage-specific hallmarks of human LIPA loss-of-function phenotypes and provides a model to tackle key challenges in human macrophage functional genomics by moving from genomic localization to mechanistic insights.
